I don't usually start new threads - but thought I would try it this time...
This isn't meant to be anything definitive but I didn't want to go off topic re Taz's thread on oestrogen and brain function
Taz you mentioned stroke risk so I looked up a few papers but it's all a bit inconclusive and you've probably seen most of it anyway - might be helpful to some though maybe?
Brain Warning - it's a long post!!!! (I'm hopeless at being brief!)
BMS and Women's Health Concern Recommendations on HRThttp://min.sagepub.com/content/19/2/59This is the paper I often quote from and here is what it says about stroke:
Stroke
Observational studies on the use of HRT and stroke have yielded conflicting results.
The WHI study revealed an overall increased incidence of stoke in women using estrogen and progestogen therapy or estrogen alone.
Re-analysis of the combined data from the estrogen and progesterone study and that of the estrogen alone study revealed a smaller increase in incidence of stroke in women who commenced HRT between the ages of 50 and 59.
The HERS study (the Heart and Estrogen progestogen Replacement Study) found no increased incidence of stroke with HRT.
On current evidence, HRT cannot be recommended for the primary or secondary prevention of stroke.
Caution should be exercised when prescribing HRT in women over the age of 60 particularly when they have a risk factor for stroke or thromboembolism. In these groups, current evidence would suggest that the transdermal route may be advantageous.
The effects of HRT may be dose related and the lowest effective dose should be prescribed in women with significant risk factors.International Menopause Society statement – Women's Health Initiative study 10 years onMay 2012
They re-analysed the data from the famous study and produced a paper which was summarised in the statement.
Stroke There is a modest increase in stroke risk with HRT use if started near the menopause. This risk rises considerably in women who start at older ages. There is some evidence that use of HRT patches (as opposed to pills) may not increase stroke risk, but this needs to be confirmed (Henderson and Lobo)I haven't seen the actual paper.
Remember that the WHI study was carried out only using conjugated equine oestrogens and synthetic progestogens and was also flawed in a number of ways
There are indications that transdermal methods of oestrogen replacement are safer:
Medical News article America Sept 2013http://www.news-medical.net/news/20130920/Hormone-replacement-therapy-formulations-may-cause-different-risks-for-stroke-heart-attack.aspI've missed out a few paragraphs
A new observational study shows bioidentical hormones in transdermal patches may be associated with a lower risk of heart attack and FDA-approved products -- not compounded hormones -- may be associated with a slightly lower risk of stroke compared to synthetic hormones in pill form.
"If confirmed by future randomized trials, these findings may be significant because for the past decade, many women who experienced severe menopause symptoms opted not to use hormone therapy because of the reported increased risk of stroke and heart attacks,"
Shufelt said the study's findings are not conclusive and are based on observational follow-up, not a randomized clinical trial. Additionally, all types of hormone therapy had similar rates of total cardiovascular outcomes and all-cause mortality, the study showed. The similarities in results across formulations were greater than the differences
Today there are many hormone options in the form of pills, patches and creams, synthetic or bioidentical, low dose or higher dose, and we wanted to answer whether they all have the same risk. This study is important because it is the first of its kind to provide a head-to-head comparison of the different doses and delivery methods. We found low dose and the transdermal patch may carry less risk for some outcomes than traditional hormone therapy, but more research is needed," Shufelt said
.
"Our analysis of the data shows that women taking oral estradiol, the bioidentical as opposed to synthetic form of estrogen, may have a trend toward a slightly lower risk of having a stroke. Also, taking estradiol through a patch on the skin was associated with a slightly lower risk of heart disease when we compared it to taking a synthetic hormone in pill form." But the numbers of women using these newer forms of hormone therapy were small.
The researchers concluded that the FDA-approved estradiol form of estrogen, and the transdermal delivery of hormones, may not carry that same increased risk for heart attack and stroke seen with oral regimens, but stressed that the findings are inconclusive and must be confirmed by randomized trials.
Shufelt said that this study adds to a growing body of evidence suggesting that hormone therapy taken through a patch, in smaller doses, may have less adverse effects on a woman's risk for developing cardiovascular disease than traditional hormone therapy.Danish Study:http://www.ncbi.nlm.nih.gov/pubmed/23048011Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial.
Conclusions: After 10 years of randomised treatment, women receiving hormone replacement therapy early after menopause had a significantly reduced risk of mortality, heart failure, or myocardial infarction, without any apparent increase in risk of cancer, venous thromboembolism, or stroke The women in the study were all recently post-menopausal age 45-58 (average age 50) and were followed for 10 years then 16 years. The abstract of paper does not distinguish between results according to age
NICE Clinical Knowledge SummariesVenous thromboembolismhttp://cks.nice.org.uk/menopause#!supportingevidence1:11Oral and not transdermal hormone replacement therapy (HRT) is associated with an increased risk of venous thromboembolism (VTE) in case-control studies.That's it for now - all I could find and decipher without getting in too much brain fog!
Hope it's useful to someone....
Hurdity x